HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised OutlookBenzinga • 11/07/24
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the EpidemicBusiness Wire • 11/07/24
Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass EstimatesZacks Investment Research • 11/06/24
Gilead's third-quarter earnings beat by a wide margin, and biotech raises guidanceMarket Watch • 11/06/24
Gilead Sciences Easily Beats Third-Quarter Views Driven By Solid Biktarvy SalesInvestors Business Daily • 11/06/24
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?Zacks Investment Research • 11/05/24
Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-WorldBusiness Wire • 11/05/24
Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to DeclineZacks Investment Research • 10/30/24
Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024Business Wire • 10/22/24
Gilead, MRK Report Data From Investigational Combination Study for HIVZacks Investment Research • 10/21/24
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48Business Wire • 10/19/24